Editas Medicine's investment thesis is centered on the high-risk, high-reward potential of its CRISPR gene editing pipeline, but this is fundamentally challenged by a deteriorating financial profile.
Price trend, volume and key moving averages
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 5, 2026 | -$0.15+44.5% vs -$0.27 | $12M+317.7% vs $3M |
Q2 2026 May 5, 2026 | -$0.26+13.3% vs -$0.30 | $3M-55.6% vs $6M |
Q2 2026 Mar 9, 2026 | -$0.06+77.8% vs -$0.27 | $25M+196.3% vs $8M |
Q4 2025 Nov 10, 2025 | -$0.28+26.3% vs -$0.38 | $8M-10.8% vs $8M |
Editas Medicine, Inc. (NASDAQ: EDIT - Get Free Report) crossed below its fifty day moving average during trading on Friday. The stock has a fifty day moving average of $2.83 and traded as low as $2.33. Editas Medicine shares last traded at $2.35, with a volume of 1,551,331 shares trading hands. Wall Street Analyst Weigh In
CAMBRIDGE, Mass., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced two poster presentations at the European Society of Gene and Cell Therapy (ESGCT) 33rd Annual Congress, to be held October 27-30, 2026, in Hamburg, Germany.
Editas Medicine gains approval to launch the first-in-human phase I/II study of EDIT-401 in Australia, targeting LDL cholesterol through gene editing.
Phase 1/2 clinical trial of EDIT-401 cleared to initiate dosing in patients who require additional LDL-C lowering Company remains on track to begin patient dosing this year and report initial safety and tolerability data in the first quarter of 2027 New EDIT-401 preclinical data demonstrating durability of LDL-C reduction to be presented in oral presentation at AHA Scientific Sessions 2026 CAMBRIDGE, Mass., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced it has received approval to initiate the Phase 1/2 Strive™ clinical trial of EDIT-401 in patients with Heterozygous Familial Hypercholesterolemia (HeFH) in Australia.
Benchmark EDIT against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Editas Medicine, Inc. (EDIT)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $2.57 | $394.4M | -4.15 | 25.39% | -157.32% | -196.63% | — | |
| $50.07 | $4.83B | -10.62 | -89.97% | -1812.07% | -25.59% | — | |
| $26.41 | $2.72B | -25.82 | 120.01% | -73.04% | -9.69% | — | |
| $11.35 | $1.27B | -3.73 | 16.92% | -805.75% | -64.73% | — | |
| $2.38 | $259.88M | -15.80 | — | — | -5.76% | — | |
| $1.84 | $214.47M | -1.83 | -51.24% | -2619.64% | -73.92% | — |
Editas Medicine, Inc. (EDIT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Editas Medicine, Inc. (EDIT) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 5, 2026·SEC
Jun 18, 2026·SEC
May 26, 2026·SEC
Get notified when EDIT posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Editas Medicine, Inc. (EDIT) stock FAQ — growth, dividends, profitability & financials explained
Editas Medicine, Inc. (EDIT) reported $47.0M in revenue over the trailing twelve months. Revenue was $40.5M in fiscal year 2025.
Editas Medicine, Inc. (EDIT) grew revenue by 20.8% over the trailing twelve months, compared with the twelve months before.
No. Editas Medicine, Inc. (EDIT) reported a net loss of $73.9M over the trailing twelve months.
Editas Medicine, Inc. (EDIT) had a return on equity (ROE) of -196.6% over the trailing twelve months. A negative ROE means the company lost money over the period.
Editas Medicine, Inc. (EDIT) had negative free cash flow of $120.5M over the trailing twelve months.
